The impact of sleeve gastrectomy on polycystic ovarian syndrome: a single-center 1-year cohort study.

Abstract

Obesity is one of the risk factors for polycystic ovarian syndrome (PCOS), and weight loss is the mainstay of treatment. This study investigates the effects of sleeve gastrectomy on clinical and paraclinical signs and symptoms of PCOS patients referred to a tertiary hospital. Female patients with a definite diagnosis of PCOS and body mass index (BMI) > 40kg/m2 who were candidates for sleeve gastrectomy were enrolled in this cohort study and followed for 1year postoperatively. Clinical signs and symptoms of PCOS, sonographic examination, and laboratory hormonal assessments were assessed preoperatively and 1year following surgery. Fifty patients enrolled in the study. The mean age of patients was 31.69 ± 9.54years. The mean BMI before and after the surgery was 44.28 ± 3.03 and 29.37 ± 2.41kg/m2, respectively. Oligomenorrhea was improved in 66% of patients. According to the sonographic criteria, PCOS was improved in 74% of patients. After a year post-operation, while the mean serum levels of the follicular stimulating hormone (FSH), testosterone, and dehydroepiandrostenedione have improved significantly in all patients (p < 0.001 in all), the significant decrease in serum luteinizing hormone (LH), LH/ FSH ratio, and estrogen was only noted in patients with improved clinical response (p < 0.05, p < 0.001, and p < 0.001 respectively). Weight loss and improvements in hyperandrogenism following sleeve gastrectomy result in clinical and paraclinical improvement of PCOS signs and symptoms, including oligomenorrhea and ovulation induction.